Medical Doctor Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Ronald Patrick

Dermatology Ruskin, FL Medical Doctor

NPI 1285648956 CMS profile 194701

924 Cypress Village Blvd Ste A, Ruskin, FL 33573

Open in the dashboard

General payments

$313

10 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Ronald Patrick of Ruskin, FL is reported in the CMS Open Payments database as having received $313 across 10 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 19th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $140 2
2023 General $80 4
2022 General $67 3
2021 General $26 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Patrick
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Ronald Patrick were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Ronald Patrick Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $26 $377 $108–$1,108 $132
2022 $67 $514 $143–$1,391 $149
2023 $80 $607 $159–$1,674 $160
2024 $140 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Revance Therapeutics, Inc. $124 1 payment
  2. AbbVie, Inc. $50 2 payments
  3. Galderma Laboratories, L.P. $48 3 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $28 1 payment
  5. Allergan Inc. $26 1 payment
  6. Pfizer Inc. $20 1 payment
  7. Sun Pharmaceutical Industries Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $313 10 payments
Products named General payments · program years 2021–2024
  1. DAXXIFY $124 1 payment
  2. SPEVIGO $28 1 payment
  3. BOTOX $26 1 payment
  4. CIBINQO $20 1 payment
  5. EUCRISA $20 1 payment
  6. BLU-U $17 1 payment
  7. Odomzo $17 1 payment
  8. NATRELLE SALINE-FILLED BREAST IMPLANTS $16 1 payment
  9. DYSPORT $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

829

Median for Dermatology: 534

Drug cost

$27,518

Median for Dermatology: $67,151

Branded share of claims

8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ivermectin Generic 15 $8,693
Metronidazole Generic 59 $3,261
Clobetasol Propionate Generic 69 $2,750
Ketoconazole Generic 133 $2,234
Fluorouracil Generic 22 $1,452
Betamethasone Dipropionate Generic 35 $922
Ammonium Lactate Generic 24 $852
Azelaic Acid Generic 13 $803
Doxycycline Hyclate Generic 41 $788
Triamcinolone Acetonide Generic 91 $784

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$799,018

Of which drugs: $30,737

Medicare patients

2,083

Average age 79

Services billed

15,127

1,168 women, 915 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Chronic kidney disease 35%
Ischemic heart disease 34%
Diabetes 23%
Atrial fibrillation 23%
COPD 22%
Depression 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 41 54 $16,230

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

10 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record